Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to ...

On Tuesday, Organon & Co (OGN) stock saw a decline, ending the day at $16.46 which represents a decrease of $-0.46 or -2.72% from the prior close of $16.92. The stock opened at $16.74 and touched a ...

Organon Philippines, a women’s health company, recently unveiled its Her Health Finder, an online tool that aims to empower ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab). In ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), reducing the price target to $17.00.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Organon & Co (Symbol: OGN) presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

On a per-share basis, the Jersey City, New Jersey-based company said it had profit of $1.38. Earnings, adjusted for one-time gains and costs, came to 87 cents per share. The results exceeded Wall ...